Neutralizing activity of sera from sputnik v-vaccinated people against variants of concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow endemic SARS-CoV-2 variants

Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B.1.1.7, B.1.617.3 and local genetic lineages B.1.1.141 (T385I), B.1.1.317 (S477N, A522S) with RBD mutations. For the B.1.351, P.1, and B.1.617.2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from “Sputnik V”-vaccinated retain neutralizing activity against VOC B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 as well as local genetic lineages B.1.1.141 and B.1.1.317 circulating in Moscow. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Авторы
Gushchin V.A.1, 2 , Dolzhikova I.V.1 , Shchetinin A.M.1 , Odintsova A.S.1 , Siniavin A.E.1, 3 , Nikiforova M.A.1 , Pochtovyi A.A.1, 2 , Shidlovskaya E.V.1 , Kuznetsova N.A.1 , Burgasova O.A. 1, 4, 5 , Kolobukhina L.V.1, 4 , Iliukhina A.A.1 , Kovyrshina A.V.1 , Botikov A.G.1 , Kuzina A.V.1 , Grousova D.M.1 , Tukhvatulin A.I.1 , Shcheblyakov D.V.1 , Zubkova O.V.1 , Karpova O.V.4 , Voronina O.L.1 , Ryzhova N.N.1 , Aksenova E.I.1 , Kunda M.S.1 , Lioznov D.A.6, 7 , Danilenko D.M.6 , Komissarov A.B.6 , Tkachuck A.P.1 , Logunov D.Y.1 , Gintsburg A.L.1, 8
Журнал
Издательство
MDPI AG
Номер выпуска
7
Язык
Английский
Статус
Опубликовано
Номер
779
Том
9
Год
2021
Организации
  • 1 Federal State Budget Institution, “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, Moscow, 123098, Russian Federation
  • 2 Department of Virology, Biological Faculty, Lomonosov Moscow State University, Moscow, 119991, Russian Federation
  • 3 Department of Molecular Neuroimmune Signalling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997, Russian Federation
  • 4 Moscow Healthcare Department, Moscow, 127006, Russian Federation
  • 5 Department of Infectious Diseases, Peoples’ Friendship University of Russia (RUDN University), Moscow, 117198, Russian Federation
  • 6 Smorodintsev Research Institute of Influenza, St. Petersburg, 197022, Russian Federation
  • 7 Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University, St. Petersburg, 197022, Russian Federation
  • 8 Department of Infectiology and Virology, Federal State Autonomous Educational Institution of Higher Education I M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, 119435, Russian Federation
Ключевые слова
COVID-19; SARS-CoV-2; Sputnik V; Vaccine; Virus neutralizing activity; VOC
Дата создания
16.12.2021
Дата изменения
12.07.2024
Постоянная ссылка
https://repository.rudn.ru/ru/records/article/record/76760/
Поделиться

Другие записи